PEDIATRIC (<18 YEARS OF AGE) GROWTH HORMONE PRIOR AUTHORIZATION REQUEST FORM

OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328

Optum Rx®

UnitedHealthcare® Community Plan

Today's Date
☐☐ / ☐☐ / ☐☐☐☐

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be returned****

Patient's Medicaid # ☐☐☐☐☐☐☐☐☐☐☐☐	Date of Birth ☐☐ / ☐☐ / ☐☐☐☐
Patient's Name	Prescriber's Name
Prescriber's IN License # ☐☐☐☐☐☐☐☐	Specialty
Prescriber's NPI # ☐☐☐☐☐☐☐☐☐☐	Prescriber's Signature
Return Fax # ☐☐☐ - ☐☐☐ - ☐☐☐☐	Return Phone # ☐☐☐ - ☐☐☐ - ☐☐☐☐
Check box if requesting retro-active PA ☐	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

Requested Medication and Strength	Dosage	Treatment Duration

SOMATROPIN AGENTS – Initial Authorization

Please select the member's diagnosis:

- ☐ Growth hormone deficiency
- ☐ Noonan syndrome (Norditropin only)
- ☐ Prader-Willi syndrome
- ☐ Renal function impairment associated with growth failure (Nutropin AQ only)
- ☐ Short-stature homeobox-containing gene (SHOX) deficiency (Humatrope or Zomacton only)
- ☐ Small for gestational age (SGA)
- ☐ Turner syndrome
- ☐ Other* (please provide diagnosis)_____
- ☐ N/A

Diagnosis of Idiopathic short stature ☐ Yes ☐ No ☐ N/A

The following documentation will be required for the above diagnosis

- Confirmatory growth chart documentation is required illustrating both of the following:
  - Height measurement of more than 2.0 standard deviations below population mean for given age
  - Growth rate of 5 cm/year or less prior to starting growth hormone therapy

Please complete the following:

Current height: _____ (inches)

Height 6 months prior: _____(inches)

Height 12 months prior: _____(inches)

Diagnosis of HIV-associated wasting or cachexia (Serostim only) ☐ Yes ☐ No ☐ N/A

***The following documentation will be required for the above diagnosis**

- Quantitative measurement of lean body mass using DEXA (dual energy X-ray absorptiometry) or BIA (bioelectric impedance analysis)
- Documentation of involuntary weight loss of >10% of baseline total body weight OR body cell mass <30% for initial approval

Member's current AIDS/HIV anti-retroviral regimen: _____

Member has tried and failed the one other therapy for HIV-associated wasting or cachexia [e.g., anabolic steroids (include medication name, trial date, dose, frequency, duration, reason for failure)]

_____

_____

The following documentation will be required for any of the above diagnoses (except for HIV-associated wasting or cachexia indication being treated by Serostim):

- Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required
- Radiology report documenting a bone age of 14-15 or less in members assigned female at birth, 16-17 or less in members assigned male at birth
- Radiology report documenting open epiphyses (NOTE: documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)

Please select one of the following for ALL indications:

☐ Request is for a preferred agent

☐ Request is for a non-preferred agent with a product-specific indication:
List indication:_____

☐ Prescriber would like to utilize a non-preferred agent over preferred agent based on the following medical justification:

_____

_____

For ALL indications – Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy ☐ Yes ☐ No

I, _____hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.

Prescriber Signature: _____

SOMATROPIN AGENTS – Reauthorization

Please select one of the following:

☐ Member has a diagnosis from initial authorization **other than** HIV-associated wasting or cachexia

Please select one of the following:

☐ Request is for a preferred agent

☐ Request is for a non-preferred agent with a product-specific indication:

List indication:_____

☐ Prescriber would like to utilize a non-preferred agent over preferred agent based on the following medical justification:

_____

_____

The following documentation will be required for diagnoses other than HIV-associated wasting or cachexia:

- Radiology report documenting a bone age of 14-15 or less in members assigned female at birth, 16-17 or less in members assigned male at birth
- Radiology report documenting open epiphyses (NOTE: documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)

The following documentation will be required for idiopathic short stature diagnosis ONLY

- Growth rate of 2 to 2.5 cm/year or more with growth hormone therapy ☐ Yes ☐ No

If **no**, please provide valid medical justification for continued use:

_____

_____

For ALL indications other than HIV-associated wasting or cachexia Prescriber attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate

☐ Yes ☐ No

I, _____hereby attest that I am continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.

Prescriber Signature:_____

☐ Member has a **diagnosis of HIV-associated wasting or cachexia** and is continuing growth hormone therapy

- Member's current AIDS/HIV anti-retroviral regimen: _____

- Member has demonstrated an increase in total body weight or lean body mass from treatment baseline **(documentation required)**

The following documentation will be required for a diagnosis of HIV-associated wasting or cachexia:

Current:	height: _____(inches)	weight:_____(lbs)
3 months prior:	height: _____(inches)	weight:_____(lbs)
6 months prior:	height: _____(inches)	weight:_____(lbs)

INCRELEX (MECASERMIN) – Initial Authorization

Diagnosis of growth failure due to severe primary insulin-like growth factor-1 deficiency (primary IGFD) OR growth hormone (GH) gene deletion with acquired neutralizing antibodies to GH ☐ Yes ☐ No

Member is greater than or equal to 2 years of age and less than 18 years of age ☐ Yes ☐ No

The following documentation will be required for the above diagnosis

- Radiology report documenting open epiphyses
- Documentation of baseline height and weight

Please complete the following:

- Baseline height: _____ (inches)
- Baseline weight: _____(kg or lb)

INCRELEX (MECASERMIN) – Reauthorization

Member is less than 18 years of age ☐ Yes ☐ No

Improvement in annualized growth velocity (AGV) OR provider has submitted valid medical justification for continued use ☐ Yes ☐ No

Please complete the following:

- Current height: _____ (inches)
- Height 6 months prior: _____(inches)
- Height 12 months prior: _____(inches)

The following documentation will be required for the above diagnosis

- Radiology report documenting open epiphyses

NGENLA (SOMATROGON-GHLA) – Initial Authorization

Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No

Member is 3 years of age or older and less than 18 years of age ☐ Yes ☐ No

The following documentation will be required for the above diagnosis

- Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required
- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Previous trial and failure of Skytrofa (lonapegsomatropin) ☐ Yes ☐ No

- If yes, please provide chart documentation or dates of use_____
- If no, please provide medical justification as to why Skytrofa (lonapegsomatropin) is unsuitable for use:

  _____

  _____

Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy ☐ Yes ☐ No

I, _____hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.

Prescriber Signature: _____

NGENLA (SOMATROGON-GHLA) – Reauthorization

The following documentation will be required for any of the indicated diagnoses

- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Member is less than 18 years of age ☐ Yes ☐ No

Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate ☐ Yes ☐ No

I, _____hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.

Prescriber Signature: _____

SKYTROFA (LONAPEGSOMATROPIN-TCGD) – Initial Authorization

Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No

Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No

- Weight: _____ (kg or lb)

The following documentation will be required for the above diagnosis

- Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required
- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Trial and failure of at least ONE preferred somatropin product ☐ Yes ☐ No

- If yes, please provide chart documentation or dates of use_____
- If no, please provide medical justification as to why the available preferred somatropin agent(s) are unsuitable for use:

  _____

  _____

Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy ☐ Yes ☐ No

I, _____hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.

Prescriber Signature: _____

SKYTROFA (LONAPEGSOMATROPIN-TCGD) – Reauthorization

The following documentation will be required for any of the indicated diagnoses

- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Member is less than 18 years of age ☐ Yes ☐ No

Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate ☐ Yes ☐ No

I, _____hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.

Prescriber Signature: _____

SOGROYA (SOMAPACITAN) – Initial Authorization

Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No

Member is 2.5 years of age or older and less than 18 years of age ☐ Yes ☐ No

The following documentation will be required for the above diagnosis

- Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required
- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Previous trial and failure of Skytrofa (lonapegsomatropin) ☐ Yes ☐ No

- If yes, please provide chart documentation or dates of use_____
- If no, please provide medical justification as to why Skytrofa (lonapegsomatropin) is unsuitable for use:

  _____

  _____

Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy ☐ Yes ☐ No

I, _____hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.

Prescriber Signature: _____

SOGROYA (SOMAPACITAN) – Reauthorization

The following documentation will be required for any of the indicated diagnoses

- Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males
- Radiology report documenting open epiphyses (**NOTE:** documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))

Member is less than 18 years of age ☐ Yes ☐ No

Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate ☐ Yes ☐ No

I, _____hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.

Prescriber Signature: _____

VOXZOGO (VOSORITIDE) – Initial Authorization

Diagnosis of achondroplasia ☐ Yes ☐ No

Member is less than 18 years of age ☐ Yes ☐ No

The following documentation will be required for the above diagnosis

- Radiology report documenting open epiphyses
- Documentation of baseline height and weight

Please complete the following:

- Baseline height: _____ (inches)
- Baseline weight: _____(kg or lb)

VOXZOGO (VOSORITIDE) – Reauthorization

Member is less than 18 years of age ☐ Yes ☐ No

Improvement in annualized growth velocity (AGV) of 1.5 cm/year OR provider has submitted valid medical justification for continued use ☐ Yes ☐ No

Please complete the following:

- Current height: _____ (inches)
- Height 6 months prior: _____(inches)
- Height 12 months prior: _____(inches)

The following documentation will be required for the above diagnosis

- Radiology report documenting open epiphyses